We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health
News

Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health

Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health
News

Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Promega Signs Agreement with the Guangzhou Institute of Biomedicine and Health"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Promega Corporation has announced a collaboration agreement with the Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences.

The agreement is designed to co-develop compound profiling solutions for small molecule and traditional Chinese medicine drug screening.

By combing the drug discovery expertise of GIBH with the biological assay expertise of Promega, the partnership is intended to deliver turnkey services to pharmaceutical companies interested in speeding up their lead discovery and lead optimization processes.

GIBH scientists will offer contract services designed to profile the biology of potential leads using the Promega suite of biological drug screening assays. Initial plans call for development of Cytochrome P450, Cytotoxicity, Kinase and GPCR profiling assays.

GIBH will use the assays both in house for own discovery programs as well as offer them on a contract basis to outside companies.

Advertisement